OTR3® is a French biotech company that has developed a new class of therapeutic agents used for skin and corneal healing. The therapeutic approach, called "Matrix therapy" is based on RGTA® (ReGeneraTing Agents), engineered biodegradable sugar-based nano-polymers, mimicking heparan-sulfates. After an injury, RGTA® target the wound, replace the degradated heparan-sulfates, bind to the proteins and growth factors and protect the matrix proteins from degradation. They restore the scaffold organization and the micro-environment of the cells allowing the tissue to rebuild. OTR3 has placed on the market medical devices indicated for the treatment of hard to heal chronic cutaneous ulcers and corneal ulcers. OTR3's Pipeline include innovative therapeutic products for ischemic stroke (Project awarded a H2020 SME Instrument grant), Acute respiratory distress syndrome (ARDS) and chronic ulcer for epidermolysis bullosa (Project awarded a PIA Leader Innov'Up grant).
View Top Employees from OTR3Website | http://www.otr3.com |
Revenue | $2 million |
Employees | 28 (28 on RocketReach) |
Founded | 2000 |
Address | 4, rue Française, Paris, Ile-de-France 75001, FR |
Phone | +33 1 83 64 23 00 |
Technologies |
JavaScript,
HTML,
PHP
+9 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare |
Web Rank | 9 Million |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies |
Looking for a particular OTR3 employee's phone or email?
The OTR3 annual revenue was $2 million in 2024.
Laurent Pinchard is the Chief Operating Officer and Chief Business Officer of OTR3.
28 people are employed at OTR3.
OTR3 is based in Paris, Ile-de-France.
The NAICS codes for OTR3 are [5417, 54171, 54, 541, 541713].
The SIC codes for OTR3 are [87, 873].